Aslan Pharmaceuticals Is A Clinical Stage Biopharmaceutical Company Based In Singaporewith Additional Operations In San Mateocaliforniafounded In 2010Aslan Focuses On Developing Innovative Treatments For Allergic Inflammatory And Autoimmune Diseasesthe Company Is Publicly Traded On Nasdaq Under The Ticker Aslnfollowing Its Ipo In 2018 Aslan Specializes In Type 2 Inflammation Driven Diseaseswith A Pipeline That Includes Eblasakimabaslan004 A First In Class Monoclonal Antibody Currently In Phase 2B Trials For Moderate To Severe Atopic Dermatitisthe Company Has Also Developed Farudodstataslan003 An Oral Dhodh Inhibitor In Phase 2A Trials For Alopecia Areataaslan Has Established A Research Collaboration With Zenyaku Kogyo In Japan For The Development And Commercialization Of Eblasakimabwith A Strong Patent Portfolio And A Dedicated Teamaslan Aims To Advance Its Clinical Candidates And Address Unmet Needs In The Field Of Immunology
